Vitamin D in nephrotic syndrome remission: a case-control study

Area of Science:

• Nephrology
• Endocrinology
• Nutritional Science

Background:

• Nephrotic syndrome (NS) is associated with potential vitamin D deficiency, a risk factor for osteoporosis.
• Understanding 25-hydroxycholecalciferol [25(OH)D] status in NS patients is crucial for bone health management.

Purpose of the Study:

• To investigate the 25(OH)D status in patients with nephrotic syndrome in remission.
• To explore the relationship between 25(OH)D levels and disease characteristics, relapse time, and other biochemical markers.

Main Methods:

• A cross-sectional case-control study involving 40 NS patients in remission and 40 healthy controls.
• Assay of serum 25(OH)D, calcium, phosphate, alkaline phosphatase (ALP), and intact parathyroid hormone (PTH).
• Analysis of NS patient data based on age, NS type, duration, relapse time, and drug therapy.

Main Results:

• Vitamin D [25(OH)D] levels were lower in NS patients within 3 months of relapse but normalized after longer remission periods.
• A positive correlation was observed between 25(OH)D levels and time elapsed since last NS relapse.
• Vitamin D levels showed a negative correlation with age and were not influenced by NS characteristics or therapy; low 25(OH)D levels (<20 ng/ml) were prevalent in 62.5% of participants.

Conclusions:

• Vitamin D stores in NS patients recover to normal levels with sustained remission beyond 3 months post-relapse.
• Disease characteristics and therapeutic interventions did not significantly impact vitamin D levels.
• Further longitudinal studies are needed to confirm these findings and assess vitamin D's skeletal impact, especially in recurrent NS cases.